Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
ANTARES PHARMA, INC. (ATRS) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/24/2022 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disp...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Amended and Restated Certificate of Incorporation of the Surviving Corporation",
"Second Amended and Restated By-Laws of the Surviving Corporation"
04/13/2022 8-K Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financi...
Docs: "Agreement and Plan of Merger, by and among Halozyme Therapeutics, Inc., Atlas Merger Sub, Inc., and Antares Pharma, Inc",
"Amendment to the Company’s Amended and Restated By-laws",
"SAN DIEGO and EWING, N.J., April 13, 2022"
03/07/2022 8-K Quarterly results
03/03/2022 8-K Quarterly results
01/11/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "80.0 2015 2016 2017 2018 2019 2020 9M"
12/16/2021 8-K Quarterly results
11/04/2021 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "ANTARES PHARMA REPORTS THIRD QUARTER 2021 FINANCIAL AND OPERATING RESULTS"
11/02/2021 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Ob...
Docs: "WELLS FARGO BANK, NATIONAL ASSOCIATION,"
10/28/2021 8-K Appointed a new director
Docs: "ANTARES PHARMA ANNOUNCES APPOINTMENT OF CARMEN VOLKART TO ITS BOARD OF DIRECTORS"
10/18/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "ANTARES PHARMA ENTERS INTO EXCLUSIVE LICENSE AGREEMENT WITH LIPOCINE FOR TLANDO® IN U.S."
08/18/2021 8-K Quarterly results
08/05/2021 8-K Quarterly results
06/15/2021 8-K Quarterly results
06/01/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
03/05/2021 8-K Quarterly results
03/02/2021 8-K Quarterly results
01/11/2021 8-K Quarterly results
11/12/2020 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Antares Pharma, Inc. Investor Presentation, November 2020"
11/05/2020 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "ANTARES PHARMA REPORTS STRONG THIRD QUARTER 2020 FINANCIAL AND OPERATING RESULTS"
10/01/2020 8-K Quarterly results
09/21/2020 8-K Quarterly results
08/06/2020 8-K Quarterly results
06/16/2020 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/05/2020 8-K Quarterly results
04/09/2020 8-K Departure of a VP
03/04/2020 8-K Quarterly results
03/03/2020 8-K Quarterly results
01/27/2020 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "ANTARES PHARMA ANNOUNCES FULL-YEAR 2020 NET REVENUE GUIDANCE RANGE OF $135 to $155 MILLION The Company Expects 2019 Net Revenue at Upper End or Exceed Range of $115 - $120 Million Guidance"
01/13/2020 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Antares Pharma, Inc. Investor Presentation, January 2020"
11/05/2019 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "ANTARES PHARMA REPORTS THIRD QUARTER 2019 OPERATING AND FINANCIAL RESULTS"
09/10/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Antares Pharma, Inc. Investor Presentation, September 2019"
08/06/2019 8-K Quarterly results
07/05/2019 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Lease Agreement, by and between Antares Pharma, Inc. and Whitewater Properties I, LLC"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy